Riskpilot← Back to searchSign inGet full accessNB PUBLIC EQUITY KOMPLEMENTAR ApS
APSActiveCVR 31748208Strandvejen 125Office administrative and support activities · NACE 8210Est. 20081 employees
Revenue 2024
DKK 131K
-28% vs 2023
EBITDA margin
-65.0%
-25% vs 2023
Equity ratio
63.4%
Financial strength
Net profit 2024
DKK -2K
0% vs 2023
| Revenue | DKK 131K | -28% |
| EBITDA | DKK -85K | -25% |
| Net profit | DKK -2K | +0% |
| Total assets | DKK 1,7M | -31% |
| Equity | DKK 1M | +0% |
| Employees | 1 | — |
Legal name
NB PUBLIC EQUITY KOMPLEMENTAR ApS
CVR number
31748208
Legal form
Anpartsselskab
NACE code
8210 · Office administrative and support activities
Founded
3. september 2008
Share capital
DKK 125.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede direktion.
Company purpose
Selskabets formål er at være komplementar i NB Public Equity K/S.
Address
Strandvejen 125
Phone
+4533186138
Email
cm@nordicbiotech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.878 | 1.934 | 356 | 364 | 366 | 613 | 678 | 414 | 490 | 301 | 267 | 181 | 131 |
| Staff expenses | -1.865 | -1.921 | -346 | -360 | -363 | -610 | -675 | -412 | -475 | -287 | -264 | -249 | -216 |
| EBITDA | 13 | 13 | 10 | 4 | 2 | 3 | 2 | 3 | 15 | 14 | 2 | -68 | -85 |
| Depreciation & amort. | -13 | -13 | -10 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | 0 | 0 | 4 | 2 | 3 | 2 | 3 | 15 | 14 | 2 | -68 | -85 |
| Net financials | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13 | -12 | -4 | -66 | 83 |
| Profit before tax | -0 | 0 | 0 | 4 | 2 | 3 | 2 | 3 | 2 | 2 | -1 | -2 | -2 |
| Tax | 1 | 27 | -0 | 0 | -0 | -0 | -0 | -0 | 0 | -22 | -0 | -1 | -1 |
| Net profit | -1 | -27 | 0 | 4 | 2 | 3 | 2 | 3 | 2 | 23 | -1 | -2 | -2 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.571 | 1.541 | 1.647 | 1.826 | 1.606 | 1.713 | 1.668 | 1.779 | 1.615 | 1.502 | 1.876 | 2.406 | 1.655 |
| Equity | 1.041 | 1.015 | 1.015 | 1.018 | 1.021 | 1.023 | 1.026 | 1.028 | 1.030 | 1.054 | 1.053 | 1.051 | 1.049 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 530 | 526 | 633 | 807 | 585 | 690 | 643 | 751 | 585 | 449 | 824 | 1.356 | 606 |
| Total debt | 530 | 526 | 633 | 807 | 585 | 690 | 643 | 751 | 585 | 449 | 824 | 1.356 | 606 |
EBITDA margin
-65.0%
This company
15.8%
Market median
-511% vs market
20122024
Equity ratio
63.4%
This company
38.2%
Market median
+66% vs market
20122024
Return on equity
-0.2%
This company
18.4%
Market median
-101% vs market
20122024
Net profit margin
-1.4%
This company
8.1%
Market median
-117% vs market
20122024
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
20122024
Debt / equity
0.58×
This company
0.62×
Market median
+6% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CL Management | Management | 2010 | — | — |
JM Founder | Founder | 2008 | — | — |
VB Management | Management | 2021 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NORDIC BIOTECH ADVISORS ApS | Company | 100.0% | 100.0% | 2008 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Holdingselskabet af 1 januar 2016 ApSTECH GROWTH INVEST ApSNORDIC BIOTECH ADVISORS ApS
NB PUBLIC EQUITY KOMPLEMENTAR ApS (this company)Board members of NB PUBLIC EQUITY KOMPLEMENTAR ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Cora Louise Madsen | Management | 0 companies |
| Jakob Mosegaard Larsen | Founder | 0 companies |
| Vibeke Bisgaard Ackermann | Management | 0 companies |